PARP1 and familial pancreatic carcinoma: While PARP inhibitors have emerged as a maintenance strategy after a platinum-based regimen in pancreatic cancer, as demonstrated in the POLO trial [42], the effectiveness of combining PARP inhibitors with immunotherapy in BTC requires investigation.